Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Gen Physiol Biophys ; 43(4): 353-366, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38953577

RESUMO

This study aimed to assess the prophylactic effects of Berberine on experimentally induced lung sepsis and examine its effects on selected cytokines, genes, and protein expression besides the histopathological evaluation. Berberine significantly reduced the wet/dry lung ratio, the broncho-alveolar lavage fluid (BALF) protein, cells, neutrophils percentage, and cytokines levels. In addition, pretreatment with Berberine decreased the myeloperoxidase (MPO) and malondialdehyde (MDA) levels and decreased gene expression of nuclear factor kappa B (NF-κB), monocyte chemoattractant protein-1 (MCP-1), and the intracellular adhesion molecule 1 (ICAM-1) by RT-qPCR analysis, revealing Berberine's antioxidant and anti-inflammatory mode of action. Western blot analysis revealed increased peroxisome proliferator-activated receptor gamma (PPAR-γ) expression in the Berberine pretreated group compared to the cecal ligation and puncture (CLP) group, in which the histopathological examination evidenced this improvement. In conclusion, Berberine improved lung sepsis via its PPAR-γ mediated antioxidant and anti-inflammatory effects.


Assuntos
Lesão Pulmonar Aguda , Berberina , PPAR gama , Sepse , Transdução de Sinais , Berberina/farmacologia , Berberina/uso terapêutico , Animais , PPAR gama/metabolismo , Sepse/metabolismo , Sepse/tratamento farmacológico , Ratos , Lesão Pulmonar Aguda/metabolismo , Lesão Pulmonar Aguda/tratamento farmacológico , Lesão Pulmonar Aguda/prevenção & controle , Masculino , Transdução de Sinais/efeitos dos fármacos , Regulação para Cima/efeitos dos fármacos , Ratos Wistar , Ratos Sprague-Dawley
2.
Cell Biochem Funct ; 41(2): 211-222, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-36588325

RESUMO

Irritable bowel syndrome (IBS) is a global gastrointestinal disorder closely related to psychological stress exposure and local colonic inflammation. Herein, we investigated the effect of wrap-restraint stress (WRS) on rat behavior, on adenosine monophosphate-activated protein kinase-mammalian/mechanistic target of rapamycin-signal transducer and activator of transcription 3 (AMPK-mTOR-STAT3) signaling, and autophagy in colonic mucosa. The impact of chronic administration of vitamin D3 and lactoferrin was compared. Twenty-four male Wistar rats were randomly divided into four groups. Chronic WRS protocol was applied as a rodent model of IBS. Group I: naïve animals, Group II: WRS animals, Group III: WRS-exposed and treated with vitamin D3 (500 IU/kg/day), and Group IV: WRS-exposed and treated with lactoferrin (300 mg/kg/day). In this study, we found that chronic administration of each of vitamin D3 and lactoferrin resulted in a significant increase in social interaction test, interleukin-10, AMPK, optical density of LC3B, goblet cell count and marked decrease in serum cortisol level, STAT3, inflammatory cell count, and optical density of mTOR in comparison to the WRS rats. Our findings suggest that both vitamin D3 and Lactoferrin could augment colonic autophagy through enhanced AMPK expression and inhibition of mTOR-STAT3 signaling, which offers practical insights into their clinical use in the prevention and therapy of IBS. However, lactoferrin intake as a nutritional supplement could be more helpful for stress-induced colitis treatment than vitamin D3.


Assuntos
Colite , Síndrome do Intestino Irritável , Ratos , Masculino , Animais , Ratos Wistar , Proteínas Quinases Ativadas por AMP/metabolismo , Lactoferrina/metabolismo , Lactoferrina/farmacologia , Vitamina D , Fator de Transcrição STAT3/metabolismo , Serina-Treonina Quinases TOR/metabolismo , Autofagia , Mamíferos/metabolismo
3.
Fundam Clin Pharmacol ; 38(4): 703-717, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38357833

RESUMO

BACKGROUND: Rho kinase (ROCK) pathway plays a critical role in post-COVID-19 pulmonary fibrosis (PCPF) and its intervention with angiotensin-converting enzyme 2 (ACE2) and vascular endothelial growth factor (VEGF) will be a potential therapeutic target. OBJECTIVES: The present study was conducted to investigate the efficacy of zoledronate (ZA) on carbon tetrachloride (CCl4) induced pulmonary fibrosis (PF) in rats through targeting ACE2, ROCK, and VEGF signaling pathways. METHODS: Fifty male Wistar rats were divided into five groups: control, vehicle-treated, PF, PF-ZA 50, and PF-ZA 100 groups. ZA was given in two different doses 100 and 50 µg/kg/week intraperitoneally. After anesthesia, mean arterial blood pressure (MBP) was measured. After scarification, lung coefficient was calculated. Lung levels of ACE 2, interleukin-1ß (IL-1ß), transforming growth factor-ß (TGF-ß), VEGF, glutathione (GSH), and superoxide dismutase (SOD) were measured. Expression of ROCK, phosphorylated myosin phosphatase target subunit 1 (P-MYPT1), and matrix metalloproteinase (MMP-1), along with histopathological changes and immune-histochemical staining for lung α-smooth muscle actin (α-SMA), tumor necrosis factor-alpha (TNFα), and caspase-3, were evaluated. RESULTS: ZA significantly prevented the decrease in MBP. ZA significantly increased ACE2, GSH, and SOD and significantly decreased IL-1ß, TGF-ß, and VEGF in lung in comparison to PF group. ZA prevented the histopathological changes induced by CCl4. ZA inhibited lung expression of ROCK, P-MYPT1, MMP-1, α-SMA, TNFα, and caspase-3 with significant differences favoring the high dose intervention. CONCLUSION: ZA in a dose-dependent manner prevented the pathological effect of CCl4 in the lung by targeting mevalonate pathway. It could be promising therapy against PCPF.


Assuntos
Modelos Animais de Doenças , Ácido Mevalônico , Fibrose Pulmonar , Ratos Wistar , Ácido Zoledrônico , Quinases Associadas a rho , Animais , Masculino , Ratos , Fibrose Pulmonar/tratamento farmacológico , Fibrose Pulmonar/metabolismo , Quinases Associadas a rho/metabolismo , Ácido Zoledrônico/farmacologia , Ácido Mevalônico/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , COVID-19/complicações , Transdução de Sinais/efeitos dos fármacos , Tratamento Farmacológico da COVID-19 , Pulmão/efeitos dos fármacos , Pulmão/patologia , Pulmão/metabolismo , Enzima de Conversão de Angiotensina 2/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA